Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Retinal disease starts metabolically, not structurally. Eye care is shifting toward a metabolic model of ocular disease, where metabolic stress precedes functional decline, which in turn precedes visible structural damage. Retinal oximetry is emerging as a promising tool to detect this early physiologic dysfunction — potentially catching diseases like diabetic retinopathy, AMD, and glaucoma before they leave a structural mark.
For decades, eye care has been built around what clinicians can see — structural imaging of the retina via OCT and similar tools. But a growing body of evidence suggests that by the time structural damage is visible, the disease process is already well underway. The new paradigm: metabolic stress comes first, functional decline follows, and structural damage appears last.
The retina is among the most metabolically active tissues in the body, relying on a precise balance of oxygen delivery, glucose metabolism, and mitochondrial function. When that balance is disrupted — even subtly — the retina may begin to compensate silently, long before any structural change shows up on imaging. This is the concept of retinal reserve: the tissue's capacity to absorb stress before it decompensates. Enter retinal oximetry, a tool that measures real-time oxygen saturation in retinal tissue and vessels. Unlike structural imaging, oximetry can reveal how the retina is functioning — not just what it looks like.
Key Takeaways:
Why it matters: If clinicians can detect retinal metabolic stress before structural damage occurs, there's a real window to intervene earlier and preserve vision — a potential game-changer for managing chronic eye diseases.
